[1]Funk ML,Rosenberg DM,Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants[J]. J Viral Hepat,2002,9(1):52-61.[2]娄晓丽,梁冬雨,侯彦强. 诱骗受体3在疾病检测中的发展[J]. 中华检验医学杂志,2011,34(10):877-880.[3]Lin WW,Hsieh SL. Decoy receptor 3:a pleiotropic immunomodulator and biomarker for inflammatory diseases,autoimmune diseases and cancer[J]. Biochem Pharmacol,2011,81(7):838-847.[4]Chang YC,Hsu TL,Lin HH,et al. Modulation of macrophage differentiation and activation by decoy receptor 3[J]. J Leukoc Biol ,2004,75(3):486-494.[5]Chang YC,Chen TC,Lee CT,et al. Epigenetic control of MHC class Ⅱ expression in tumor-associated macrophages by decoy receptor 3[J]. Blood,2008,111(10):5054-5063.[6]Kim S,Fotiadu A,Kotoula V. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia[J]. Clin Immunol,2005,115(3):286-294.[7]Bamias G,Kaltsa G,Siakavellas SI,et al. High intestinal and systemic levels of decoy receptor 3(DcR3)and its ligand TL1A in active ulcerative colitis[J]. Clin Immunol,2010,137(2):242-249.[8]Yang M,Chen G,Dang Y,et al. Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients[J]. Ups J Med Sci,2010,115(4):232-237.